<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431403</url>
  </required_header>
  <id_info>
    <org_study_id>IMACEL</org_study_id>
    <nct_id>NCT02431403</nct_id>
  </id_info>
  <brief_title>ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-labeled, multicenter, phase I/II study of imatinib combined with ESHAP as salvage
      therapy in relapsed/refractory non-Hodgkin's lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Up to 33 weeks</time_frame>
    <description>Adverse events are recorded and analyzed from the time of enrollment to last day of ESHAP-imatinib treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I/II Overall Response Rate (ORR)</measure>
    <time_frame>Week 4, Week 10, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Event-Free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>ESHAP-Imatinib 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib 100 mg combined with ESHAP
* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESHAP-Imatinib 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib 200 mg combined with ESHAP
* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESHAP-Imatinib 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib 400 mg combined with ESHAP
* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESHAP-Imatinib 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib 300 mg combined with ESHAP
* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESHAP-Imatinib</intervention_name>
    <description>After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.</description>
    <arm_group_label>ESHAP-Imatinib 100mg</arm_group_label>
    <arm_group_label>ESHAP-Imatinib 200mg</arm_group_label>
    <arm_group_label>ESHAP-Imatinib 400mg</arm_group_label>
    <arm_group_label>ESHAP-Imatinib 300mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically diagnosed non-Hodgkin's lymphoma, refractory or relapsed after 1st line
             treatment.

          2. Paraffin block of the lesions available for immunohistochemical analysis

          3. Candidate for ESHAP salvage therapy

          4. Evidence of at least one lesion with a diameter of 1.5 cm

          5. Age of over 20 years

          6. Eastern cooperative oncology group performance status (ECOG) less than or equal to 2.

          7. Adequate kidney function with serum creatinine&lt; 2.5 mg/dL, creatinine clearance ≥ 50
             mL/min

          8. Adequate liver function with aspartate transaminase (AST)/alanine aminotransferase
             (ALT) lower than or equal to 3 times the normal upper limit; Total bilirubin lower
             than or equal to 1.5 times the upper limit ;alkaline phosphatase lower than or equal
             to 5 times the normal upper limit.

          9. Adequate bone marrow function with absolute neutrophil count ≥ 1,000/uL; platelets ≥
             75,000/uL; hemoglobin ≥ 9.0 g/dL

         10. Patients who gave voluntarily informed consent before performing any test test that is
             not part of routine care of patients

        Exclusion Criteria:

          1. Patients with history of exposure to imatinib or other Bcr-Abl tyrosine-kinase
             inhibitors

          2. Known or suspected hypersensitivity to imatinib

          3. Potential use or usage alteration of CYP3A4 inducers or inhibitors from prior to 21
             days of to the test regimen until the initiation of round 2 ESHAP. Exceptions are
             itraconazole and fluconazole for treatment or prevention of fungal infection,
             hydrocortisone and dexamethasone for treatment of nausea/vomiting/fluid retention, and
             methylprednisolone as a part of the ESHAP regimen.

          4. Known involvement of the central nervous system (CNS) by lymphoma.

          5. Pregnant or breast-feeding. Females of childbearing potential who do not agree to
             undergo pregnancy tests or repeated use effective birth control while included in the
             clinical trial.

          6. Serious or uncontrolled medical condition, such as presence of abnormal or clinically
             significant cardiac disease, such as acute myocardial infarction or unstable angina
             within 6 months prior to initiation of treatment with ESHAP-imatinib, serious
             neurological or psychological conditions such as dementia or epilepsy, or uncontrolled
             active infection.

          7. Prior history of malignancy other than to non-Hodgkin's lymphoma (except basal or
             squamous cell skin and in situ carcinoma of the cervix) unless the patient free of
             disease beyond 5 years are.

          8. HIV positive and in treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jooseop Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National Universty Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyunhee Jung</last_name>
    <phone>+82-51-240-7053</phone>
    <email>jung77@pnuh.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Sook Park</last_name>
      <email>dongahicrc5@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Hwa Kong</last_name>
      <phone>+82-51-890-6987</phone>
      <email>velika-jh@nate.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saet Byeol Park</last_name>
      <email>siou7777@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Younghee Kim</last_name>
      <phone>+82-51-240-7899</phone>
      <email>shinyspring@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Sun Jeon</last_name>
      <email>uuh3103@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Edling CE, Hallberg B. c-Kit--a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 2007;39(11):1995-8. Epub 2007 Jan 20. Review.</citation>
    <PMID>17350321</PMID>
  </reference>
  <reference>
    <citation>Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma. 1998 Aug;30(5-6):459-66. Review.</citation>
    <PMID>9711908</PMID>
  </reference>
  <reference>
    <citation>Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991 Dec 1;78(11):2962-8.</citation>
    <PMID>1720040</PMID>
  </reference>
  <reference>
    <citation>Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood. 1994 Feb 1;83(3):785-92.</citation>
    <PMID>7507733</PMID>
  </reference>
  <reference>
    <citation>Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y, Aozasa K, Nomura T. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 2000 May 1;60(9):2345-7.</citation>
    <PMID>10811105</PMID>
  </reference>
  <reference>
    <citation>Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997 Jun 15;89(12):4514-20.</citation>
    <PMID>9192775</PMID>
  </reference>
  <reference>
    <citation>Aozasa K, Zaki MA. Epidemiology and pathogenesis of nasal NK/T-cell lymphoma: a mini-review. ScientificWorldJournal. 2011 Feb 14;11:422-8. doi: 10.1100/tsw.2011.41. Review.</citation>
    <PMID>21336457</PMID>
  </reference>
  <reference>
    <citation>Brauns TC, Schultewolter T, Dissemond J, Maschke J, Goos M. C-KIT expression in primary cutaneous T-cell lymphomas. J Cutan Pathol. 2004 Oct;31(9):577-82.</citation>
    <PMID>15330987</PMID>
  </reference>
  <reference>
    <citation>Choe YS, Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Do YR, Kwon KY, Song HS, Lee MH, Park TI. c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas. Leuk Lymphoma. 2006 Feb;47(2):267-70.</citation>
    <PMID>16321856</PMID>
  </reference>
  <reference>
    <citation>Giantin M, Aresu L, Aricò A, Gelain ME, Riondato F, Comazzi S, Dacasto M. Evaluation of tyrosine-kinase receptor c-kit mutations, mRNA and protein expression in canine lymphoma: might c-kit represent a therapeutic target? Vet Immunol Immunopathol. 2013 Aug 15;154(3-4):153-9. doi: 10.1016/j.vetimm.2013.05.014. Epub 2013 May 30.</citation>
    <PMID>23791075</PMID>
  </reference>
  <reference>
    <citation>Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008 May 15;22(10):1276-312. doi: 10.1101/gad.1653708. Review.</citation>
    <PMID>18483217</PMID>
  </reference>
  <reference>
    <citation>Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S, Went P, Klein U, Zinzani PL, Baccarani M, Dalla Favera R, Pileri SA. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007 Mar;117(3):823-34. Epub 2007 Feb 15.</citation>
    <PMID>17304354</PMID>
  </reference>
  <reference>
    <citation>Huang Y, de Reyniès A, de Leval L, Ghazi B, Martin-Garcia N, Travert M, Bosq J, Brière J, Petit B, Thomas E, Coppo P, Marafioti T, Emile JF, Delfau-Larue MH, Schmitt C, Gaulard P. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010 Feb 11;115(6):1226-37. doi: 10.1182/blood-2009-05-221275. Epub 2009 Nov 30.</citation>
    <PMID>19965620</PMID>
  </reference>
  <reference>
    <citation>Chen YP, Chang KC, Su WC, Chen TY. The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas. Ann Hematol. 2008 Dec;87(12):985-90. doi: 10.1007/s00277-008-0539-z. Epub 2008 Jul 17.</citation>
    <PMID>18633616</PMID>
  </reference>
  <reference>
    <citation>Passam FH, Alexandrakis MG, Kafousi M, Fotinou M, Darivianaki K, Tsirakis G, Roussou PA, Stathopoulos EN, Siafakas NM. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract. 2009;205(1):11-20. doi: 10.1016/j.prp.2008.07.007. Epub 2008 Oct 23.</citation>
    <PMID>18950958</PMID>
  </reference>
  <reference>
    <citation>Renné C, Willenbrock K, Küppers R, Hansmann ML, Bräuninger A. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood. 2005 May 15;105(10):4051-9. Epub 2005 Jan 27.</citation>
    <PMID>15677564</PMID>
  </reference>
  <reference>
    <citation>Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002 Jul;1(7):493-502. Review.</citation>
    <PMID>12120256</PMID>
  </reference>
  <reference>
    <citation>Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013 Jun 27;121(26):5192-202. doi: 10.1182/blood-2013-03-490763. Epub 2013 Apr 30.</citation>
    <PMID>23632889</PMID>
  </reference>
  <reference>
    <citation>Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia. 2004 Mar;18(3):409-14.</citation>
    <PMID>14712290</PMID>
  </reference>
  <reference>
    <citation>Shimizu H, Popova M, Fleury F, Kobayashi M, Hayashi N, Sakane I, Kurumizaka H, Venkitaraman AR, Takahashi M, Yamamoto K. c-ABL tyrosine kinase stabilizes RAD51 chromatin association. Biochem Biophys Res Commun. 2009 May 1;382(2):286-91. doi: 10.1016/j.bbrc.2009.03.020. Epub 2009 Mar 11.</citation>
    <PMID>19285032</PMID>
  </reference>
  <reference>
    <citation>Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ, Amrein L, Aloyz R, Panasci L. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol. 2011 Sep;68(3):643-51. doi: 10.1007/s00280-010-1530-7. Epub 2010 Dec 1.</citation>
    <PMID>21120481</PMID>
  </reference>
  <reference>
    <citation>Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, Martínez J, López J, Suárez JG, Moreno MJ, Merino MA, Gutiérrez NC, Hernández-Rivas JM. Response to imatinib mesylate in patients with hypereosinophilic syndrome. Int J Hematol. 2012 Sep;96(3):320-6. doi: 10.1007/s12185-012-1141-7. Epub 2012 Jul 18.</citation>
    <PMID>22806436</PMID>
  </reference>
  <reference>
    <citation>Hollmann CA, Tzankov A, Martínez-Marignac VL, Baker K, Grygorczyk C, Grygorczyk R, Foulkes W, Nadeau J, Dirnhofer S, Aloyz R. Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. Leuk Res. 2010 May;34(5):585-93. doi: 10.1016/j.leukres.2009.08.030. Epub 2009 Sep 16.</citation>
    <PMID>19758698</PMID>
  </reference>
  <reference>
    <citation>Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117-22.</citation>
    <PMID>3334893</PMID>
  </reference>
  <reference>
    <citation>Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun;12(6):1169-76.</citation>
    <PMID>8201379</PMID>
  </reference>
  <reference>
    <citation>Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul;6(6):609-11.</citation>
    <PMID>8573542</PMID>
  </reference>
  <reference>
    <citation>Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000 Nov 1;18(21):3633-42.</citation>
    <PMID>11054436</PMID>
  </reference>
  <reference>
    <citation>Zhu Y, Qian SX. Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients. Onco Targets Ther. 2014 Mar 6;7:395-404. doi: 10.2147/OTT.S38846. eCollection 2014. Review.</citation>
    <PMID>24623982</PMID>
  </reference>
  <reference>
    <citation>Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22.</citation>
    <PMID>17242396</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>May 3, 2015</last_update_submitted>
  <last_update_submitted_qc>May 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Hospital</investigator_affiliation>
    <investigator_full_name>Jooseop Chung</investigator_full_name>
    <investigator_title>Professor department of hematooncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

